Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pancreatic Cancer Metastatic × Irinotecan × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 192 Rectal Neoplasms 75 Colonic Neoplasms 68 Stomach Neoplasms 51 Pancreatic Neoplasms 41 Esophageal Neoplasms 35 Neoplasm Metastasis 34 Neoplasms 25 Lung Neoplasms 23 Small Cell Lung Carcinoma 18 Glioblastoma 18 Adenocarcinoma Of Esophagus 18 Glioma 16 Esophageal Squamous Cell Carcinoma 16 Carcinoma, Non-Small-Cell Lung 16 Neuroblastoma 15 Brain Neoplasms 14 Breast Neoplasms 13 Sarcoma 10 Gliosarcoma 10 Biliary Tract Neoplasms 10 Central Nervous System Neoplasms 8 Medulloblastoma 7 Astrocytoma 7 Adenocarcinoma 7 Recurrence 6 Oligodendroglioma 6 Locally Advanced Rectal Cancer 6 Colorectal Cancer Metastatic 6 Sarcoma, Ewing 5

Interventions

surufatinib 1 folfirinox 1 Oxaliplatin 1 Irinotecan 1 Immune Checkpoint Inhibitors 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04469556 2026-02-20

PASS-01

University Health Network, Toronto

Phase 2 Completed

Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡